Project Grant R01HL174859
Award Date
8/1/25
Completion Date
5/31/29
Dollars Obligated
$773K
Federal Agency
National Heart Lung and Blood Institute
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
Cambridge, MA 02138, USA
Similar Awards
This Project Grant award of $438,000 from the National Institutes of Health (NIH) Office of Research Infrastructure Programs (CFDA 93.351) supports the development of conditional animal models of mitochondrial DNA diseases at the University of Texas at Austin. The project aims to use CRISPR gene editing tools to introduce precise edits in the mitochondrial genome of zebrafish, enabling the creation of the first conditional animal model for mitochondrial disorders like mitochondrial...
This federal Project Grant award from the National Heart Lung and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) provides $259,464 to The Leland Stanford Junior University to conduct research on "Mitochondrial Therapy in Conjunction with Guideline Directed Medical Therapy in Cardiomyopathy". The primary objectives are to: 1) Determine the mechanism of the protective effects of mitochondria-rich extracellular vesicles (M-EVs) in combination with guideline-directed...
This Project Grant award of $601,563 was provided by the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research federal grant program (CFDA 93.837), with a project period from September 1, 2024 to August 31, 2027. The award supports research to investigate the pathogenic roles and molecular mechanisms of the histone lysine demethylases KDM5A and KDM5B in the development and progression of heart failure, with a focus on hereditary cardiomyopathies like Lamin...
This $2,369,779.54 Project Grant, awarded by the National Heart Lung and Blood Institute under CFDA 93.837 - Cardiovascular Diseases Research, supports research to develop a nonviral delivery approach for introducing CRISPR-Cas9 gene editing components into hepatocytes ex vivo, combined with acetaminophen selection, to treat familial hypercholesterolemia. The project aims to directly compare the efficiency and specificity of different nonviral delivery methods, including lipid nanoparticles,...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) supports research into the role of mitochondrial signaling between cardiomyocytes and fibroblasts in cardiac fibrosis. The $639,621 award, granted on May 15, 2025, will fund a research project led by Cleveland Clinic Lerner College of Medicine of Case Western Reserve University to investigate how intact mitochondria released from cardiomyocytes mediate...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) provides $667,704 to The Trustees of the University of Pennsylvania, doing business as the Clinical Practices of the University of Pennsylvania, to develop chemically inducible split base editors for precise and controllable in vivo genome editing. The goal is to address the root cause of hypertrophic cardiomyopathy (HCM), a genetic heart condition affecting 1 in...
This Project Grant award from the National Institutes of Health (NIH) under the Research Infrastructure Programs (CFDA 93.351) supports the development of innovative in vivo animal models for studying mitochondrial DNA (mtDNA) diseases. The $629,508 award to the University of Texas at Austin, effective September 16, 2024 through August 31, 2028, aims to generate designer zebrafish models with specific mtDNA variants to enable new research approaches for diagnosing and treating these complex...
This federal Project Grant award of $2,249,307, provided by the National Heart Lung and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research), aims to study the premature maturation arrest of pluripotent-derived cardiomyocytes (PSC-CMs) and develop strategies to overcome this issue. The project will leverage a high-resolution single cell transcriptome map of endogenous cardiomyocyte maturation to identify a critical gene regulatory network underlying the maturation failure in PSC-CMs....
The Massachusetts General Hospital will receive $3,024,000 through a three-year Project Grant from the National Institutes of Health Trans-NIH Research Support program to develop scalable methods for engineering and characterizing novel CRISPR-associated protein variants. The goal is to address limitations of current CRISPR-Cas enzymes by optimizing machine learning-guided directed evolution to create a catalog of customizable DNA editors with improved properties like expanded target...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $599,921 to The General Hospital Corporation (doing business as Massachusetts General Hospital) to conduct research on the role of METTL3, an RNA modification enzyme, in diabetic cardiomyopathy and the cardiac benefits of exercise in diabetes. The research aims to determine how METTL3 regulates the pathophysiology of diabetic...